Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients

Keyphrases

• Retreatment 100%
• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Anti-VEGF Therapy 100%
• Clinical Trial Results 100%
• Response to Treatment 66%
• Anatomic 66%
• Optical Coherence Tomography 66%
• Clinical Examination 66%
• Retina 33%
• Clinical Assessment 33%
• Ongoing Clinical Trials 33%
• Blocking Agent 33%
• Early Signs 33%
• Bevacizumab 33%
• Number of Injections 33%
• Intravitreal Ranibizumab 33%
• Injection Protocol 33%
• Dosing Schedule 33%
• Anti-vascular Endothelial Growth Factor Therapy 33%
• Visual Improvement 33%
• Intravitreal Injection 33%
• Design Analysis 33%
• Ranibizumab 33%
• Retinal Anatomy 33%
• Visual Gain 33%
• Neovascular AMD 33%
• Marina 33%
• Pro Re Nata 33%
• ANCHOR Trial 33%
• Practical Assessment 33%

Medicine and Dentistry

• Vasculotropin 100%
• Retreatment 100%
• Wet Macular Degeneration 100%
• Clinical Trial Results 100%
• Clinician 66%
• Optical Coherence Tomography 66%
• Clinical Examination 66%
• Ranibizumab 66%
• Clinical Trial 33%
• Bleeding 33%
• Anatomy 33%
• Clinical Assessment 33%
• Visual Acuity 33%
• Blocking Agent 33%
• Bevacizumab 33%
• Intravitreal Administration 33%

Nursing and Health Professions

• Wet Macular Degeneration 100%
• Retreatment 100%
• Vasculotropin 100%
• Clinician 66%
• Clinical Examination 66%
• Optical Coherence Tomography 66%
• Ranibizumab 66%
• Literature Review 33%
• Clinical Assessment 33%
• Visual Acuity 33%
• Blocking Agent 33%
• Bleeding 33%
• Bevacizumab 33%
• Intravitreal Drug Administration 33%